Skip to main content

Table 2 The patients overall clinical and histological characteristics

From: A prospective study of magnetic resonance imaging and ultrasonography (MRI/US)-fusion targeted biopsy and concurrent systematic transperineal biopsy with the average of 18-cores to detect clinically significant prostate cancer

Patients, n

177

Age, years

68.3 (48–89)

Prebiopsy prostate-specific antigen level, ng/mL

10.9 (1.65–218)

Prostate volume, mL

42.4 (11–134)

Positive digital rectal examination result, %

51 (28.8)

Systematic cores per prostate, n

18.4 ± 2.1

Targeted cores per prostate, n

3.84 ± 0.4

Patients without prior biopsy, n

145

Patients with prior biopsy negative for cancer, n

31

Patients under active surveillance, n

1

Previous prostate-related treatment, n

0

Gleason score, n

 6 (3 + 3)

19

 7 (3 + 4)

16

 7 (4 + 3)

14

 8 (4 + 4)

48

  ≥ 9 (4 + 5, 5 + 4, or 5 + 5)

19

Clinically significant prostate cancer, %

112 (63.3)

  1. Data were reported as mean (range) or mean ± standard deviation